Affimed falls 13% after announcing clinical update on AFM13 in CD30 lymphomas
Earlier today, Affimed announced the presentation of data updates on two clinical studies at the 15th International Conference on Malignant Lymphoma, ICML, in Lugano, Switzerland. The data from an oral and a poster presentation featured Affimed's lead innate cell engager AFM13, a first-in-class tetravalent, bispecific antibody derived from the ROCK platform that is being developed to treat CD30-positive lymphomas. AFM13 specifically binds to CD30 on tumor cells and to CD16A on innate immune cells, such as NK cells and macrophages. "The results of the completed Phase 1b study of AFM13 in combination with pembrolizumab in Hodgkin lymphoma and of Columbia University's study of AFM13 in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation substantiate the potential of AFM13 to make a difference in the lives of patients with limited to no treatment options," said Dr. Leila Alland, Affimed's Chief Medical Officer. "We look forward to advancing our innate cell engagers in future clinical studies, including our registration-directed study of AFM13 in relapsed and refractory peripheral T cell lymphoma and transformed mycosis fungoides." Shares of Affimed are down 44c per share or 12.76% to $2.98 in afternoon trading.